Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

Kazrin Inhibitors

Kazrin inhibitors represent a class of small molecules or compounds designed to target a specific cellular protein known as Kazrin. Kazrin itself is a relatively recently discovered protein with essential roles in cell adhesion and cell-cell junction formation. This protein is a key component of the desmosome, a cell-cell junction structure found in tissues like the skin, heart, and gastrointestinal tract. Desmosomes are crucial for maintaining tissue integrity and strength by facilitating strong adhesive connections between adjacent cells. Kazrin, as a structural component of desmosomes, helps to stabilize these junctions and is involved in regulating cell adhesion and migration processes.

The development of Kazrin inhibitors stems from a growing interest in understanding the molecular mechanisms underlying cell adhesion and tissue integrity. By inhibiting Kazrin's activity, researchers aim to investigate its precise role in desmosome function and cell adhesion, which could have implications for various physiological and pathological processes. These inhibitors are invaluable tools in the laboratory for studying cell biology, as they allow scientists to selectively manipulate Kazrin's function and explore its downstream effects on cell adhesion and tissue architecture.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Inhibits the tyrosine kinase activity of BCR-ABL, blocking the signaling pathways that promote cancer cell proliferation in chronic myeloid leukemia (CML).

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Targets multiple kinases, including Raf and VEGFR, disrupting tumor growth and angiogenesis in various cancers.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

Selectively inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, impeding signaling pathways involved in cancer cell proliferation and survival.

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
$117.00
$423.00
11
(1)

Specifically inhibits the mutated BRAF kinase in melanoma cells, preventing uncontrolled cell division and tumor growth.

Erlotinib Hydrochloride

183319-69-9sc-202154
sc-202154A
10 mg
25 mg
$75.00
$121.00
33
(1)

Blocks the EGFR tyrosine kinase, reducing cell growth and division in EGFR-mutated lung cancer.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Dual inhibitor of EGFR and HER2 kinases, interfering with cancer cell proliferation and metastasis in breast cancer.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Targets multiple kinases, including BCR-ABL and Src, inhibiting cell signaling pathways in leukemia and solid tumors.

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

Selectively inhibits CDK4 and CDK6, disrupting the cell cycle progression in hormone receptor-positive breast cancer.

Ibrutinib

936563-96-1sc-483194
10 mg
$156.00
5
(0)

Irreversibly inhibits BTK in B-cell malignancies, disrupting the B-cell receptor signaling pathway and inhibiting cell survival.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$251.00
$500.00
$547.00
16
(1)

Inhibits JAK1 and JAK2, interfering with cytokine signaling and reducing inflammation in myeloproliferative neoplasms.